On July 24, 2018, Allakos, a clinical-stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell-related diseases, announced the closing of its initial public offering of 8,203,332 shares of its common stock at a public offering price of $18.00 per share, which includes the full exercise of the underwriters' option to purchase up to 1,069,999 additional shares. The company estimates net proceeds from the offering to be approximately $134.4 million, after deducting the underwriting discounts and commissions and estimated offering expenses. The shares began trading on Nasdaq Global Select Market under the symbol "ALLK" on July 19 and closed at $31.23 per share on the first day of trading. Wilson Sonsini Goodrich & Rosati represented Allakos in the offering.

Goldman Sachs & Co. and Jefferies acted as joint book-running managers for the offering, while William Blair & Company acted as the lead manager for the offering.

The Wilson Sonsini team that represented Allakos in the offering included partners Ken Clark, Tony Jeffries, and Jennifer Knapp and Of Counsel Lance Brady.

For more information, please see Allakos' press release.